AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18163098 — intervention group
Group type: EXPERIMENTAL
Intervention: Protracted multiple infectious focuses in periodontal tissues
Number of subjects: 0
Study 15198753 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular pethidine 100 mg
Number of subjects: 50
Study 15198753 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 50
Study 11164124 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined weight loss and sodium reduction
Number of subjects: 900
Study 11164124 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium reduction
Number of subjects: 900
Study 11164124 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 900
Study 11164124 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 900
Study 9509973 — intervention group
Group type: EXPERIMENTAL
Intervention: BUCY (busulfan 16 mg/kg and cyclophosphamide 120 mg/kg)
Number of subjects: 49
Study 9509973 — intervention group
Group type: EXPERIMENTAL
Intervention: BEAC (carmustine 300 mg/m2, etoposide 600 mg/m2, cytarabine 600 mg/m2, and cyclophosphamide 140 mg/kg)
Number of subjects: 49
Study 9509973 — intervention group
Group type: EXPERIMENTAL
Intervention: BUCY
Number of subjects: 49
Study 9509973 — intervention group
Group type: EXPERIMENTAL
Intervention: BEAC
Number of subjects: 49
Study 7997351 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic gouge
Number of subjects: 50
Study 7997351 — intervention group
Group type: COMPARATOR
Intervention: Standard method
Number of subjects: 50
Study 31006069 — intervention group
Group type: EXPERIMENTAL
Intervention: MySpineTM 3D-printed patient-specific guides
Number of subjects: 29
Study 31006069 — intervention group
Group type: COMPARATOR
Intervention: Free-hand implantation
Number of subjects: 29
Study 28508515 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-hydrated collagenated cortico-cancellous porcine bone (coll-group)
Number of subjects: 55
Study 28508515 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical porcine bone (cort-group)
Number of subjects: 55
Study 28508515 — intervention group
Group type: COMPARATOR
Intervention: Naturally-healing group (nat-group)
Number of subjects: 55
Study 26571488 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoallergenic formula supplemented with prebiotic galacto‐oligosaccharides
Number of subjects: 0
Study 26571488 — intervention group
Group type: COMPARATOR
Intervention: Hypoallergenic formula without supplementation (Control)
Number of subjects: 0
Study 23639822 — intervention group
Group type: EXPERIMENTAL
Intervention: Motion style acupuncture treatment (MSAT)
Number of subjects: 58
Study 23639822 — intervention group
Group type: COMPARATOR
Intervention: Conventional diclofenac injection
Number of subjects: 58
Study 21974834 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-professional medication review at baseline and 6 months
Number of subjects: 30
Study 21974834 — intervention group
Group type: COMPARATOR
Intervention: Usual care (support from the National Health Service)
Number of subjects: 30
Study 21974834 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-professional medication review
Number of subjects: 30
Study 21974834 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 30
Study 18434573 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular implant overdentures
Number of subjects: 173
Study 18434573 — intervention group
Group type: COMPARATOR
Intervention: Conventional dentures
Number of subjects: 173
Study 16966504 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency STN DBS (10 Hz)
Number of subjects: 12
Study 16966504 — intervention group
Group type: COMPARATOR
Intervention: High-frequency STN DBS (130 Hz)
Number of subjects: 12
Study 16966504 — intervention group
Group type: COMPARATOR
Intervention: No stimulation
Number of subjects: 12
Study 14531810 — intervention group
Group type: EXPERIMENTAL
Intervention: Loop diuretic (furosemide or torsemide)
Number of subjects: 0
Study 14531810 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily loop diuretic administration
Number of subjects: 0
Study 14531810 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 0
Study 14531810 — intervention group
Group type: EXPERIMENTAL
Intervention: Torsemide
Number of subjects: 0
Study 11005907 — intervention group
Group type: EXPERIMENTAL
Intervention: Smith‐Nephew's Skin‐Prep (SP)
Number of subjects: 20
Study 11005907 — intervention group
Group type: EXPERIMENTAL
Intervention: Secure(2) Medical Adhesive (SMA)
Number of subjects: 20
Study 11005907 — intervention group
Group type: EXPERIMENTAL
Intervention: Epithane‐3 (E3)
Number of subjects: 20
Study 11005907 — intervention group
Group type: COMPARATOR
Intervention: Uni‐Solve adhesive remover (US)
Number of subjects: 20
Study 11005907 — intervention group
Group type: COMPARATOR
Intervention: No SP
Number of subjects: 20
Study 9013470 — intervention group
Group type: EXPERIMENTAL
Intervention: rHu GM-CSF (group 1)
Number of subjects: 28
Study 9013470 — intervention group
Group type: COMPARATOR
Intervention: Control (no rHu GM-CSF, group 2)
Number of subjects: 28
Study 9013470 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (1 and 2)
Number of subjects: 28
Study 8214465 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (ginger, metoclopramide, placebo)
Number of subjects: 120
Study 3698464 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (200 mg)
Number of subjects: 9
Study 3698464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 29652758 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportional Assist Ventilation (PAV)
Number of subjects: 54
Study 29652758 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 54
Study 29652758 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 54
Study 27494448 — intervention group
Group type: EXPERIMENTAL
Intervention: LowCHO diet (Carb:Pro:Fat:Sat-Fat 14:28:58: < 10% energy; n=58)
Number of subjects: 115
Study 27494448 — intervention group
Group type: COMPARATOR
Intervention: HighCHO diet (53:17:30: < 10%; n=57)
Number of subjects: 115
Study 24602992 — intervention group
Group type: EXPERIMENTAL
Intervention: CBTp
Number of subjects: 80
Study 24602992 — intervention group
Group type: COMPARATOR
Intervention: Wait-list group
Number of subjects: 80
Study 24602992 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined sample (immediate CBTp + delayed CBTp)
Number of subjects: 80
Study 22316334 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 0.5 g kg-1
Number of subjects: 0
Study 22316334 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 1 g kg-1
Number of subjects: 0
Study 20128531 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrara intracorneal ring segments (ICRS) implantation
Number of subjects: 37
Study 18254150 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel tablet formulation 1
Number of subjects: 0
Study 18254150 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel tablet formulation 2
Number of subjects: 0
Study 18254150 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel (general)
Number of subjects: 0
Study 15983467 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative remifentanil at 0.40 microg x kg(‐1) x min(‐1) (large-dose remifentanil)
Number of subjects: 75
Study 15983467 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative remifentanil at 0.05 microg x kg(‐1) x min(‐1) (small-dose remifentanil)
Number of subjects: 75
Study 15983467 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative remifentanil at 0.40 microg x kg(‐1) x min(‐1) and 0.5 mg/kg ketamine just after induction (large-dose remifentanil-ketamine)
Number of subjects: 75
Study 12208707 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide
Number of subjects: 1077
Study 12208707 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1077
Study 10624455 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate 150 mg/day
Number of subjects: 23
Study 10624455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 7575752 — intervention group
Group type: EXPERIMENTAL
Intervention: Indometacin 75 mg bid
Number of subjects: 12
Study 7575752 — intervention group
Group type: EXPERIMENTAL
Intervention: Indometacin 75 mg bid plus roxatidine acetate 75 mg nocte
Number of subjects: 12
Study 7575752 — intervention group
Group type: EXPERIMENTAL
Intervention: Indometacin 75 mg bid plus roxatidine acetate 75 mg bid
Number of subjects: 12
Study 1782227 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA (13‐15 mg/kg per day)
Number of subjects: 73
Study 1782227 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 7052802 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (no visual reinforcement)
Number of subjects: 20
Study 7052802 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II (with visual reinforcement)
Number of subjects: 20
Study 7052802 — intervention group
Group type: EXPERIMENTAL
Intervention: Group III (non-reinforced, 15 randomizations of List A at 16 db SL)
Number of subjects: 20
Study 7052802 — intervention group
Group type: EXPERIMENTAL
Intervention: Group IV (non-reinforced, 15 randomizations of List A at 56 db SL)
Number of subjects: 20
Study 30544141 — intervention group
Group type: EXPERIMENTAL
Intervention: Insomnia symptoms
Number of subjects: 1882
Study 30544141 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep paralysis frequency
Number of subjects: 1882
Study 30544141 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissociative experiences during wakefulness
Number of subjects: 1882
Study 30544141 — intervention group
Group type: EXPERIMENTAL
Intervention: Nightmares
Number of subjects: 1882
Study 30039165 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-early neurological deterioration (U-END) in patients with intracranial hemorrhage
Number of subjects: 1690
Study 30039165 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-early neurological deterioration (U-END)
Number of subjects: 1690
Study 27498334 — intervention group
Group type: EXPERIMENTAL
Intervention: CaO-SiO2-P2O5-B2O3 bioactive glass ceramics spacer
Number of subjects: 86
Study 27498334 — intervention group
Group type: COMPARATOR
Intervention: Titanium cage
Number of subjects: 86
Study 24603400 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing exercises
Number of subjects: 0
Study 24603400 — intervention group
Group type: COMPARATOR
Intervention: Proton pump inhibitors
Number of subjects: 0
Study 22650121 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 74
Study 22650121 — intervention group
Group type: COMPARATOR
Intervention: Warming needle moxibustion (WNM)
Number of subjects: 74
Study 20419154 — intervention group
Group type: EXPERIMENTAL
Intervention: Telaprevir (HCV protease inhibitor), specific dosage and duration not mentioned
Number of subjects: 0
Study 18656299 — intervention group
Group type: EXPERIMENTAL
Intervention: S1 intensity
Number of subjects: 57
Study 18656299 — intervention group
Group type: EXPERIMENTAL
Intervention: S1 variability
Number of subjects: 57
Study 18656299 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventricular pacing
Number of subjects: 57
Study 16242473 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical lymph node dissection
Number of subjects: 30
Study 16242473 — intervention group
Group type: COMPARATOR
Intervention: No cervical lymph node dissection
Number of subjects: 30
Study 14636105 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (VE) supplementation (1200 IU/day)
Number of subjects: 18
Study 14636105 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 18
Study 10909992 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (150 mg)
Number of subjects: 6
Study 10909992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 8878083 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g sorbitol and 20 g glucose
Number of subjects: 6
Study 8878083 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g sorbitol and 9 g lipids
Number of subjects: 6
Study 8878083 — intervention group
Group type: COMPARATOR
Intervention: 20 g sorbitol alone
Number of subjects: 6
Study 1813715 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudomonas immunoglobulin (250 mg/kg) administered intravenously on days 3, 5, 7, 10, and 13 after trauma
Number of subjects: 60
Study 1813715 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prophylaxis)
Number of subjects: 60
Study 1813715 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudomonas immunoglobulin (PIG-SUBGRP)
Number of subjects: 60
Study 1813715 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON-SUBGRP)
Number of subjects: 60
Study 6390248 — intervention group
Group type: EXPERIMENTAL
Intervention: iohexol (Omnipaque)
Number of subjects: 50
Study 6390248 — intervention group
Group type: COMPARATOR
Intervention: metrizamide (Amipaque)
Number of subjects: 50
Study 31056697 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal influenza vaccination
Number of subjects: 605
Study 31056697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 605
Study 28915853 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-targeted touch (slow brushing)
Number of subjects: 40
Study 28915853 — intervention group
Group type: COMPARATOR
Intervention: Heat-pain (HP) stimulation
Number of subjects: 40
Study 28915853 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-targeted touch combined with HP stimulation
Number of subjects: 40
Study 26460306 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized cognitive intervention (25 training sessions at home with weekly coaching)
Number of subjects: 68
Study 25325208 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-dose non-liberal-interval dosage (MDNLD) regimen (12.5 mg/Kg every 12 hours)
Number of subjects: 40
Study 25325208 — intervention group
Group type: COMPARATOR
Intervention: High-dose extended-interval dosage (HDED) regimen (25 mg/Kg every 24 hours)
Number of subjects: 40
Study 22888489 — intervention group
Group type: EXPERIMENTAL
Intervention: Merocel middle meatal spacer (MMMS)
Number of subjects: 37
Study 22888489 — intervention group
Group type: EXPERIMENTAL
Intervention: Finger glove Merocel middle meatal spacer (FGMMS)
Number of subjects: 37
Study 19254942 — intervention group
Group type: EXPERIMENTAL
Intervention: AC (doxorubicin 40 mg/m2 plus cyclophosphamide 500 mg/m2)
Number of subjects: 441
Study 19254942 — intervention group
Group type: EXPERIMENTAL
Intervention: D (single-agent docetaxel 60 mg/m2)
Number of subjects: 441
Study 19254942 — intervention group
Group type: EXPERIMENTAL
Intervention: AC-D (alternating regimen of AC and docetaxel)
Number of subjects: 441
Study 17767753 — intervention group
Group type: EXPERIMENTAL
Intervention: Bixa Orellana (BO) 250 mg 3 times a day for 12 months
Number of subjects: 136
Study 17767753 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Pbo)
Number of subjects: 136
Study 15162353 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Resistance Exercise Training (PRET)
Number of subjects: 20
Study 15162353 — intervention group
Group type: COMPARATOR
Intervention: Standard care intervention
Number of subjects: 20
Study 10764302 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium 0 microg
Number of subjects: 0
Study 10764302 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 4.5 microg
Number of subjects: 0
Study 10764302 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 9 microg
Number of subjects: 0
Study 10764302 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 18 microg
Number of subjects: 0
Study 10764302 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 36 microg
Number of subjects: 0
Study 8818066 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related physical education (P+) program
Number of subjects: 2096
Study 1425545 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsolicited, mailed, self-help smoking cessation program
Number of subjects: 1396
Study 1425545 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1396
Study 3988415 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium + Magnesium Aspartate (K + Mg Asp)
Number of subjects: 0
Study 3988415 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 30998237 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (0.67 mg/m2/day)
Number of subjects: 27
Study 30998237 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 30004039 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 2.5 mg once daily
Number of subjects: 635
Study 30004039 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 5.0 mg once daily
Number of subjects: 635
Study 30004039 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 635
Study 27329023 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care screening
Number of subjects: 781
Study 27329023 — intervention group
Group type: COMPARATOR
Intervention: Secondary care screening
Number of subjects: 781
Study 22413962 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin + Metformin
Number of subjects: 0
Study 22413962 — intervention group
Group type: COMPARATOR
Intervention: Dapagliflozin
Number of subjects: 0
Study 22413962 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 0
Study 20135967 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect decompression (group A)
Number of subjects: 52
Study 20135967 — intervention group
Group type: COMPARATOR
Intervention: Open decompression (group B)
Number of subjects: 52
Study 18338276 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine PCEA combined with lornoxicam 8 mg iv
Number of subjects: 40
Study 18338276 — intervention group
Group type: COMPARATOR
Intervention: Morphine PCEA combined with placebo (saline 2 ml iv)
Number of subjects: 40
Study 15747892 — intervention group
Group type: EXPERIMENTAL
Intervention: New prostheses (complete dentures)
Number of subjects: 26
Study 14512205 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine 15-45 mg (n = 124)
Number of subjects: 246
Study 14512205 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20-40 mg (n = 122)
Number of subjects: 246
Study 11033656 — intervention group
Group type: EXPERIMENTAL
Intervention: After-hours nursing care from nurse employees
Number of subjects: 373
Study 11033656 — intervention group
Group type: COMPARATOR
Intervention: After-hours nursing care from contract nurses
Number of subjects: 373
Study 8620226 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC 1 (0.5% tetracaine, 1:2000 adrenaline, 11.8% cocaine)
Number of subjects: 156
Study 8620226 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC 2 (1% tetracaine, 1:2000 adrenaline, 4% cocaine)
Number of subjects: 156
Study 8620226 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC 3 (1% tetracaine, 4% cocaine without adrenaline)
Number of subjects: 156
Study 1627434 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant intravenous (IV) cyclophosphamide, methotrexate, and fluorouracil (CMF) - 600 mg/m2 each of cyclophosphamide and fluorouracil, and 40 mg/m2 of methotrexate, administered IV on day 1, repeated every 3 weeks for a total of 12 treatments.
Number of subjects: 90
Study 1627434 — intervention group
Group type: COMPARATOR
Intervention: Local-regional modality alone (control group)
Number of subjects: 90
Study 2861920 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg/day propranolol
Number of subjects: 16
Study 2861920 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/day metoprolol
Number of subjects: 16
Study 2861920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 31779617 — intervention group
Group type: EXPERIMENTAL
Intervention: High fear-avoidance beliefs (FABs) about physical activity (score ≥ 15)
Number of subjects: 3066
Study 31779617 — intervention group
Group type: COMPARATOR
Intervention: Low fear-avoidance beliefs (FABs) about physical activity (score < 15)
Number of subjects: 3066
Study 27893526 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental O2 (10 l/min)
Number of subjects: 95
Study 27893526 — intervention group
Group type: COMPARATOR
Intervention: Room air
Number of subjects: 95
Study 27930743 — intervention group
Group type: EXPERIMENTAL
Intervention: β‐alanine
Number of subjects: 22
Study 24532523 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid periarticular injection (40 mg triamcinolone acetonide)
Number of subjects: 76
Study 24532523 — intervention group
Group type: COMPARATOR
Intervention: Non-steroid periarticular injection
Number of subjects: 76
Study 24532523 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid periarticular injection
Number of subjects: 76
Study 22443213 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir (Levemir)
Number of subjects: 17374
Study 22443213 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antidiabetic drugs (OADs)
Number of subjects: 17374
Study 22443213 — intervention group
Group type: EXPERIMENTAL
Intervention: Glinides
Number of subjects: 17374
Study 22443213 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphonylureas
Number of subjects: 17374
Study 22443213 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazolidinediones (TZD)
Number of subjects: 17374
Study 22443213 — intervention group
Group type: EXPERIMENTAL
Intervention: DPP-IV inhibitors
Number of subjects: 17374
Study 22443213 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c
Number of subjects: 17374
Study 20876699 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 0.5 mg kg⁻¹
Number of subjects: 93
Study 20876699 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 1.0 mg kg⁻¹
Number of subjects: 93
Study 20876699 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 2.0 mg kg⁻¹
Number of subjects: 93
Study 20876699 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 4.0 mg kg⁻¹
Number of subjects: 93
Study 20876699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 18728368 — intervention group
Group type: EXPERIMENTAL
Intervention: Miswak impregnated in 3% NaF for 3 days
Number of subjects: 9
Study 18728368 — intervention group
Group type: EXPERIMENTAL
Intervention: Miswak impregnated in 3% NaF for 1 day
Number of subjects: 9
Study 18728368 — intervention group
Group type: COMPARATOR
Intervention: 1 g of fluoride toothpaste (1,450 ppm F as NaF)
Number of subjects: 9